Nanomaterials for Protein Delivery in Anticancer Applications

被引:38
作者
Yau, Anne [1 ]
Lee, Jinhyung [1 ]
Chen, Yupeng [1 ]
机构
[1] Univ Connecticut, Dept Biomed Engn, Storrs, CT 06269 USA
基金
美国国家科学基金会;
关键词
nanomaterials; protein delivery; anticancer therapy; cancer treatment; nanotechnology;
D O I
10.3390/pharmaceutics13020155
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nanotechnology platforms, such as nanoparticles, liposomes, dendrimers, and micelles have been studied extensively for various drug deliveries, to treat or prevent diseases by modulating physiological or pathological processes. The delivery drug molecules range from traditional small molecules to recently developed biologics, such as proteins, peptides, and nucleic acids. Among them, proteins have shown a series of advantages and potential in various therapeutic applications, such as introducing therapeutic proteins due to genetic defects, or used as nanocarriers for anticancer agents to decelerate tumor growth or control metastasis. This review discusses the existing nanoparticle delivery systems, introducing design strategies, advantages of using each system, and possible limitations. Moreover, we will examine the intracellular delivery of different protein therapeutics, such as antibodies, antigens, and gene editing proteins into the host cells to achieve anticancer effects and cancer vaccines. Finally, we explore the current applications of protein delivery in anticancer treatments.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 160 条
  • [1] Solid lipid nanoparticles as a drug delivery system for peptides and proteins
    Almeida, Antonio J.
    Souto, Eliana
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) : 478 - 490
  • [2] Gold nanoparticle mediated cancer immunotherapy
    Almeida, Joao Paulo Mattos
    Figueroa, Elizabeth Raquel
    Drezek, Rebekah Anna
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2014, 10 (03) : 503 - 514
  • [3] Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
    Alomari, Ahmed K.
    Cohen, Justine
    Vortmeyer, Alexander O.
    Chiang, Anne
    Gettinger, Scott
    Goldberg, Sarah
    Kluger, Harriet M.
    Chiang, Veronica L.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (06) : 481 - 487
  • [4] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [5] Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework
    Alsaiari, Shahad K.
    Patil, Sachin
    Alyami, Mram
    Alamoudi, Kholod O.
    Aleisa, Fajr A.
    Merzaban, Jasmeen S.
    Li, Mo
    Khashab, Niveen M.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (01) : 143 - 146
  • [6] Oxidized Carbon Black: Preparation, Characterization and Application in Antibody Delivery across Cell Membrane
    Amornwachirabodee, Kittima
    Tantimekin, Nattapol
    Pan-In, Porntip
    Palaga, Tanapat
    Pienpinijtham, Prompong
    Pipattanaboon, Chonlatip
    Sukmanee, Thanyada
    Ritprajak, Patcharee
    Charoenpat, Promchat
    Pitaksajjakul, Pannamthip
    Ramasoota, Pongrama
    Wanichwecharungruang, Supason
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [7] Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide
    Andrew, Jennifer S.
    Anglin, Emily J.
    Wu, Elizabeth C.
    Chen, Michelle Y.
    Cheng, Lingyun
    Freeman, William R.
    Sailor, Michael J.
    [J]. ADVANCED FUNCTIONAL MATERIALS, 2010, 20 (23) : 4168 - 4174
  • [8] [Anonymous], IMMUNOTHERAPY POSSIB, DOI [10.1200/JCO.2017.35.15_suppl.TPS1126, DOI 10.1200/JCO.2017.35.15_SUPPL.TPS1126]
  • [9] [Anonymous], PHASE 1B STUDY PVX 4
  • [10] [Anonymous], 2018, COMBINING CRLX101